Abstract

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Effect of Prior Therapy on the Efficacy and Safety of Oral Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Study
Federica Cavallo ...
Blood | VOL. 134
Federica Cavallo, et. al.Federica Cavallo ...
13 Nov 2019
LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy
Philippe Moreau ...
Blood | VOL. 138
Philippe Moreau, et. al.Philippe Moreau ...
05 Nov 2021
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Thierry Facon ...
Blood | VOL. 132
Thierry Facon, et. al.Thierry Facon ...
29 Nov 2018
The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression
Michel Delforge ...
Blood | VOL. 134
Michel Delforge, et. al.Michel Delforge ...
13 Nov 2019
View more papers

More From: Blood

Paper Title
Journal
Date
Author
JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results.
Joseph A Pidala ... Brian C Betts
Blood | VOL. -
Joseph A Pidala, et. al.Joseph A Pidala ... Brian C Betts
24 Jul 2024
Critical Role of Tripartite Fusion and LBD Truncation in Certain RARA- and all RARG-Related Atypical APL.
Xiaosu Zhou ... Hongxing Liu
Blood | VOL. -
Xiaosu Zhou, et. al.Xiaosu Zhou ... Hongxing Liu
24 Jul 2024
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
Franco Locatelli ... Christina Diaz-De-Heredia
Blood | VOL. -
Franco Locatelli, et. al.Franco Locatelli ... Christina Diaz-De-Heredia
24 Jul 2024
A predictive model for therapy failure in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor therapy.
Xiaoshuai Zhang ... Qian Jiang
Blood | VOL. -
Xiaoshuai Zhang, et. al.Xiaoshuai Zhang ... Qian Jiang
24 Jul 2024
View more papers